This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Applied Clinical Trials Magazine Advises Clinical Trials To Put Patients First In New Peer-Reviewed Article

ISELIN, N.J., April 3, 2013 /PRNewswire/ -- Clinical trials are the cornerstone of getting biopharmaceuticals approved to treat diseases now and develop new medicines and knowledge for the future. Many people are unfamiliar with clinical trials until they or a loved one face a life-or-death disease diagnosis. Then the choices to treat their condition become more confusing and urgent. This is true even for professionals who work in and understand clinical trials. In Applied Clinical Trials magazine, Linda Strause, PhD, Executive Director & Head, Clinical Operations, Vical Inc., and Research Scientist & Founder, Institute of Palliative Medicine & San Diego Hospice IRB, discusses her personal experience when her husband, Randy, is diagnosed with glioblastoma, an incurable brain cancer.

"It's hard to imagine anyone better suited to navigating the clinical trial process than I was. I have a doctorate in neurophysiology and I am the executive director and head of clinical operations at a biotechnology company where I have been conducting oncology research for years and currently manage a Phase III melanoma trial," writes Strause.

Only 3% to 5% of cancer patients participate in clinical trials, while oncology drug development projects account for 31% of all clinical trial projects worldwide. Now on the other side of her experiences – which surround her husband's subsequent death – Strause offers advice for the industry to change clinical trials by putting patients at the center of the clinical research enterprise.

"While the movement for patient-centric healthcare is growing, it has only started to be recognized as a better way to conduct clinical trials," says Applied Clinical Trials Content Director Lisa Henderson. "The role of the patient is only going to grow in the next few years. While the content we offer is geared toward clinical trials professionals, and Linda's article offers concrete advice for those insiders, I believe the article can also help many others going through these difficult decisions."

For the full text of the article "Patient-First Approach to Improve Oncology Clinical Trials," visit on our web site

Contact: Lisa Henderson Editorial Director Email732-346-3080

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Applied Clinical Trials

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs